It's JPM 2025 and here at Fierce Biotech we’re bringing you all the latest updates live from the life sciences event of the ...

Discover three oversold biotech/biopharma stocks to watch amidst market volatility and the JP Morgan Healthcare event in San ...

This study links Ffar4, gut microbiota, and sugar preference, highlighting potential strategies for managing diabetes and ...

Roche's strategic acquisition of Poseida Pharmaceuticals positions them as a leader in the allogeneic cell therapy market.

GlobalData predicts that six late-stage pipeline products are set to enter the glaucoma market during the forecast period.